Product
SCD-101
1 clinical trial
2 indications
Indication
Sickle Cell DiseaseIndication
Sickle-Beta Zero ThalassemiaClinical trial
Part A: Phase IB, Single Site, Dose-Escalation of SCD-101 and Part B: Randomized, Double-Blind, Placebo-Controlled Crossover of SCD-101 in Adults With Homozygous Sickle Cell Disease or S/Beta 0 Thalassemia.Status: Active (not recruiting), Estimated PCD: 2023-11-01